Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in … Read more

Earnings, jobs loom large in the week ahead for a discerning market. Here’s what’s coming up

Earnings, jobs loom large in the week ahead for a discerning market. Here’s what’s coming up

More Magnificent Seven earnings are coming next week, helping to decide the direction of a stock market that’s becoming more discerning, while the latest data on the labor market will cast light on the state of the economy. Alphabet and Amazon are the next big technology companies in line to have their income statements scrutinized, … Read more

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase … Read more

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. … Read more

Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market

Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market

Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker … Read more

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after it failed to meet efficacy goals in an interim analysis. … Read more

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Nine of the largest pharma companies ink deals with Trump to lower drug prices

U.S. President Donald Trump speaks during an event in the Roosevelt Room of the White House December 19, 2025 in Washington, DC. Trump delivered remarks on lowering prescription drug prices during the event. Alex Wong | Getty Images Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump on Friday to … Read more

Stocks making the biggest moves premarket: Pfizer, Roku, Kraft Heinz & more

Stocks making the biggest moves premarket: Pfizer, Roku, Kraft Heinz & more

Check out the companies making headlines before the bell: Pfizer — The pharma giant issued disappointing 2026 earnings guidance. Pfizer a profit between $2.80 per share and $3 per share for the coming year. Analysts polled by LSEG expected earnings per share of $3.05 for 2026. The company also reaffirmed its 2025 outlook. Shares hovered … Read more